In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire PLC

Division of Takeda Pharmaceutical Co. Ltd.
www.shire.com

Latest From Shire PLC

Kala Needs Big STRIDE To Get Dry Eye Drug OK

The US FDA has issued a complete response letter for KPI-121 but Kala hopes to resubmit the drug during the first half of next year backed by data from the ongoing STRIDE 3 study.

Ophthalmic Strategy

TopiVert Has High Hopes For Dry Eye Drug Despite Trial Fail

A mixed set of results from a Phase IIb/III trial of TOP1630 has not deterred the privately-held firm which maintains that the anti-inflammatory kinase inhibitor is a promising treatment.

Ophthalmic Clinical Trials

Keeping Track: Turalio, Nubeqa And Accrufer Mark Trio Of Novel Drug Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Drug Review

Finance Watch: Cell And Gene Therapy Fundraising Down Overall In Q2, But VC Deals Still Soared

Private Company Edition: ARM's Q2 report shows a 38% decline in financings, but venture capital and upfront fees from deals were robust. Also, Servier raises $405m in the US, Frequency closes a $62m series C and VenatoRx accesses US government cash.

Financing Regenerative Medicine
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register